New Vision for Wet AMD Therapy
Oraya Therapeutics, Inc., is a privately held company that has developed an innovative and non-invasive therapy for wet age-related macular degeneration, or wet AMD. Founded in 2007, headquartered in Newark, California, and actively supported by leading medical technology investors, Oraya is dedicated to advancing the treatment of wet AMD through the development and commercialization of Oraya Therapy. This approach uses a low-voltage, stereotactic, radiosurgical device designed specifically for treatment in an outpatient setting. Oraya Therapy delivers a precise dose of radiation non-invasively to the macula using an automated positioning system, a proprietary localizing algorithm, and a novel methodology for eye stabilization and tracking.
Wet AMD is responsible for the vast majority of severe vision loss in the industrialized world, according to the AMD Alliance International. Upon onset, it can quickly lead to the rapid deterioration of visual acuity and blindness if left untreated. While there is no cure for wet AMD, the cost and burden of current treatment methods, which involve near-monthly injections into the eye, have driven the development of novel approaches. Oraya Therapy is one such new option.
The non-invasive Oraya Therapy is rapid, comfortable for the patient, and easy for a trained operator to perform. Recent clinical trials have demonstrated that the therapy can reduce the required number and frequency of anti-VEGF injections, while achieving equivalent, or improved, visual acuity and slowing disease progression. Oraya Therapy should ease the burden for patients and their families, and for retinal physicians and their practices, while significantly reducing costs for the payers.